Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • rammohanshukla
    Junior Member
    • Mar 2013
    • 4

    #1

    Deseq2 design clarification

    Hi, I am working with human postmortem samples wherein I have 5 groups of subjects:

    A. Control: 20 samples
    B. First episode: 20 samples
    C. First episode Remission: 15 samples
    D. Second episode: 20 samples
    E. Second episode Remission: 15 samples


    Note that the progression of A to B to C to D to E is expected to be in phase (something like sinusoidal curve)

    I also have other parameters for the samples, which include: Age, Sex, RIN value, PMI (postmortem interval), pH of the sample


    I wish to test the difference of the 5 groups in ANOVA like analysis in DEseq2 but after controlling for Age, Sex, RIN value, PMI (postmortem interval), pH of the sample

    My phenotype table looks like this:

    Sample Age Sex Rin PMI pH DiseaseStage
    1 binned factor binned binned binned Control
    2 Control
    3 First episode
    . First episode
    . First episode
    . .
    . .
    90 Second episode Remission



    This is my design
    dds <- DESeqDataSet(se, design = ~ Age+Sex+RIN+PMI+pH+DiseaseStage)

    dds <- DESeq(dds, test = "LRT", reduced = ~ Age+Sex+RIN+PMI+pH)
    results(dds)

    I am hoping that I get 1 p-value for ANOVA like comparisons between the disease stage after controlling for Age, Sex, RIN, PMI and pH
    Also, I would like to know how many variables I can control for in the design? For instance, here I am using 5 (Age, Sex, RIN, PMI and pH) is it okay? If yes, is there any rule to how many variables to control for in the design?

Latest Articles

Collapse

  • SEQadmin2
    Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
    by SEQadmin2



    Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

    Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
    ...
    10-14-2026, 09:55 AM
  • SEQadmin2
    New Genomics Technologies Take Aim at Long-Standing Limits
    by SEQadmin2


    Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.

    We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing
    ...
    09-28-2026, 10:25 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by SEQadmin2, 10-22-2026, 11:13 AM
0 responses
26 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-22-2026, 10:48 AM
0 responses
20 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-15-2026, 10:52 AM
0 responses
36 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-14-2026, 05:39 AM
0 responses
43 views
0 reactions
Last Post SEQadmin2  
Working...